user
menu
letter
Sign InRegister
langEnglisharrow

Monoamine oxidase B

Monoamine oxidase B

Monoamine oxidase B Overview

Molecule Name
Monoamine oxidase B
Synonyms
MAOB, MAO-B,Monoamine Oxidase B,Monoamine oxidase type B
Drug Development Progress
Drugs in Clinical Trials13
Approved Drugs3
Highest Development StageApproved
Target Synonym
EC:1.4.3.4，EC 1.4.3，MAOB，Amine oxidase [flavin-containing] B，Monoamine Oxidase B，Monoamine Oxidase Type B，MAO-B，Adrenalin Oxidase，Tyramine Oxidase，MAO， Platelet，MAO， Brain，EC 1.4.3.4
Background
Monoamine Oxidase Type B (MAOB) is an enzyme located in the outer mitochondrial membrane. It catalyzes the oxidative deamination of biogenic and xenobiotic amines and plays an important role in the breakdown of dopamine in the brain. MAOB inhibitors, that reduces dopamine turnover, are in clinical use for the treatment of Parkinson's disease (PD).

Monoamine oxidase B Product List

Species
  • Human（1）
Tag
  • His Tag（1）
Host
  • InsectCells（1）
Conjugate
  • Unconjugated（1）
Grade
  • RUO（1）
Low Endotoxin
  • No（1）
MoleculeCat. No.Product NameSpeciesHostStructurePurityActivitySize&Price
Monoamine oxidase B
MAB-H5547
Human MAOB / Monoamine Oxidase B Protein, His Tag (active enzyme)
Human
InsectCells
SDS-PAGE
Enzyme

$245.00

20ug
You Have Viewed 1-1 Of 1 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

Product InquiryRequest Customization
Asset Licensing Opportunity

Project Cooperation

Project NameDrug TypeTherapeutic AreaIndicationStageRights Area
Reversible MAOB InhibitorSmall moleculeNeurological diseaseParkinson's diseasePhase IGlobal
Project Name
Reversible MAOB Inhibitor
Drug Type
Small molecule
Therapeutic Area
Neurological disease
Indication
Parkinson's disease
Stage
Phase I
Rights Area
Global
Resources

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
Pramipexole Dihydrochloride Hydrate/Rasagiline MesylateP2B-001Phase 3 ClinicalPharma Two B Ltd
Parkinson Disease
Details
VafidemstatORY-2001Phase 2 ClinicalOryzon Genomics Sa
Alzheimer Disease; Borderline Personality Disorder; Kabuki syndrome; Schizophrenia
Details
J-147J-147Phase 2 ClinicalSalk Institute
Alzheimer Disease; Ischemic Stroke
Details
TisolagilineKDS2010; KDS-2010Phase 2 ClinicalNeuroBiogen
Alzheimer Disease; Cognitive Dysfunction; Dementia; Obesity; Overweight
Details
Rasagiline transdermal patch (Teikoku Pharma)Phase 1 ClinicalTeikoku Pharma
Parkinson Disease
Details
SKL-PDYKP-10461; SKL-PDPhase 1 ClinicalSK Biopharmaceuticals Co Ltd
Parkinson Disease
Details
18F-FCOB0418F-FCOB04; 18F-FCOB-04Phase 1 ClinicalPeking Union Medical College Hospital
Neurodegenerative Diseases
Details
LNTH-2511Phase 1 ClinicalLantheus Holdings Inc
Neuroinflammatory Diseases
Details
Pramipexole and Rasagiline Mesylate Sustained-release Capsules(Zhejiang Jingxin Pharma)Phase 1 ClinicalZhejiang Jingxin Pharmaceutical Co Ltd
Parkinson Disease
Details
Rasagiline Mesylate Sublingual membrane(Shanghai Shangyao Zhongxi Pharma)Phase 1 ClinicalShanghai Shangyao Zhongxi Pharmaceutical Co Ltd
Parkinson Disease
Details
Rasagiline Mesylate Transdermal Patch(world leader)Phase 1 ClinicalGuizhou Shiling Pharmaceutical Co Ltd, Shanghai World Ling Pharmaceutical Co Ltd
Parkinson Disease
Details
HEC-122505MsOHHEC-122505MsOH; HEC-122505-MsOH; HEC122505MsOHPhase 1 ClinicalGuangdong Dongyangguang Pharmaceutical Co Ltd
Parkinson Disease
Details
18F-SMBT-118F-SMBT-1; 18-F-SMBT-1ClinicalTohoku University
Details

Marketed Drug Information

English NameResearch CodeHighest Development StageCompanyFirst Brand NameFirst Approved CountryFirst IndicationFirst Approved CompanyFirst Approved DateIndicationClinical Trial
Rasagiline MesylateLu 00-773; TVP-101; TV-1030; AGN-1135; TVP-1012ApprovedTevaAzilect, AgilectEUParkinson DiseaseTeva Bv2005-02-21
Alzheimer Disease; Dementia; Multiple System Atrophy; Parkinson Disease; REM Sleep Behavior Disorder; Restless Legs Syndrome; Supranuclear Palsy, Progressive; Synucleinopathies
Details
Selegiline HydrochlorideFPF-1100; E-250 (free base)ApprovedSanofiFP, Jumex, Otrasel, Seledat, Xilopar, Zelapar, Deprenyl, Eldepryl, Plurimen, Vivapryl, Zydis selegilineMainland ChinaParkinson DiseaseChinoin Pharmaceutical And Chemical Works Co Ltd1989-06-05
Amphetamine-Related Disorders; Borderline Personality Disorder; Cocaine-Related Disorders; Cognition Disorders; Depressive Disorder, Major; HIV Infections; Marijuana Abuse; Parkinson Disease; Schizophrenia; Tobacco Use Cessation; Tobacco Use Disorder
Details
Safinamide MesylatePNU-151774E; FCE-28073 (R-isomer); EMD-1195686; ZP-034; NW-1015; ME-2125; PNU-151774; FCE-26743ApprovedNewron PharmaceuticalXadago, EqufinaEUParkinson DiseaseZambon Spa2015-02-23
Dyskinesia, Drug-Induced; Hepatic Insufficiency; Multiple System Atrophy; Parkinson Disease; Renal Insufficiency
Details
Customer Reviews